With $20.7 Million Series A Cash, RaNA Seeks To Be A Groundbreaker In Long Non-Coding RNA Therapeutics
This article was originally published in The Pink Sheet Daily
Biotech hopes to begin IND-enabling studies in 2013 and bring first candidate into the clinic in 2014 in a new field it believes will have applicability in numerous therapeutic areas.
You may also be interested in...
Ag-Bio Alliance With Monsanto Brings Alnylam Cash For “5x15” Programs
Alnylam will license its IP estate to agriculture giant Monsanto over 10 years, in turn getting a $29.2 million upfront payment that it will put toward further development of RNAi therapeutics.
Start-Up Quarterly Statistics, Q1 2012
Biopharma start-ups raised $338.1 million – 51% less than in Q4 2011. Device companies brought in $123.7 million and diagnostics firms raised $99.3 million; Series C rounds generated more money in both the device and diagnostic sectors than any other financing type. Cancer was the most prevalent therapeutic area for biopharma alliances. During Q1, M&As across biopharma and diagnostic industries were valued at a total of $471 million.
Financings Of The Fortnight Applies Its Own Lens To Early-Stage Investments
Plus news on recent financings by Neurocrine Biosciences, Prosensa, RaNA Therapeutics and Trius Therapeutics.